Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Fig 3
Rintatolimod-treated patients by ETT response (≥25% vs. <25%): Comparison of change from baseline in vertical rise at Week 40 for the ITT population vs. each subset.